Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 3100Neoplasms 2446Carcinoma, Non-Small-Cell Lung 1865Prostatic Neoplasms 1629Colorectal Neoplasms 1424Lung Neoplasms 1300Multiple Myeloma 930Neoplasm Metastasis 926Leukemia, Myeloid, Acute 874Pancreatic Neoplasms 851Ovarian Neoplasms 803Melanoma 786Carcinoma, Hepatocellular 743Stomach Neoplasms 640Brain Neoplasms 640Recurrence 635Squamous Cell Carcinoma of Head and Neck 631Head and Neck Neoplasms 614Glioblastoma 569Lymphoma 543Uterine Cervical Neoplasms 541Triple Negative Breast Neoplasms 505Precursor Cell Lymphoblastic Leukemia-Lymphoma 498Carcinoma, Renal Cell 497Hematologic Neoplasms 467Urinary Bladder Neoplasms 462Endometrial Neoplasms 462Colonic Neoplasms 439Sarcoma 437Lymphoma, Non-Hodgkin 437

Interventions

tislelizumab 1Oxaliplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mid-low Rectal Cancer × 1 year × Clear all
NCT06333769 2025-08-15

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

Fujian Cancer Hospital

Phase 2 Completed
38 enrolled
Gastrointestinal

Mid-low Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡